Cindy Bayley
Keine laufenden Positionen mehr
Profil
Cindy Bayley is the founder of Elixir Pharmaceuticals, Inc. founded in 1999.
She worked as Vice President-Business Strategy at deCODE genetics, Inc. in 2010.
She also worked as Vice President-Business Strategy at deCODE Genetics ehf.
Dr. Bayley completed her undergraduate degree at the University of Rochester.
She also completed her MBA and doctorate degrees at The University of Chicago.
Ehemalige bekannte Positionen von Cindy Bayley
| Unternehmen | Position | Ende |
|---|---|---|
deCODE genetics, Inc.
 deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Corporate Officer/Principal | 13.07.2010 |
Elixir Pharmaceuticals, Inc.
 Elixir Pharmaceuticals, Inc. Investment Trusts/Mutual FundsMiscellaneous Elixir Pharmaceuticals, Inc. operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases such as diabetes and obesity. The company was founded by Leonard Guarente, Cynthia J. Kenyon, Cindy Bayley, Louis Kunkel, Annibale Puca, and Thomas Perls in 1999 and is headquartered in Cambridge, MA. | Gründer | - |
deCODE Genetics ehf
 deCODE Genetics ehf Miscellaneous Commercial ServicesCommercial Services deCODE genetics engages in a biopharmaceuticals company. It provides research services with focus on human genes. The company was founded by K?ri Stef?nsson in August 1996 and is headquartered in Reykjavik, Iceland. | Corporate Officer/Principal | - |
Ausbildung von Cindy Bayley
| The University of Chicago | Doctorate Degree |
| Rochester Christian University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |
deCODE Genetics ehf
deCODE Genetics ehf Miscellaneous Commercial ServicesCommercial Services deCODE genetics engages in a biopharmaceuticals company. It provides research services with focus on human genes. The company was founded by K?ri Stef?nsson in August 1996 and is headquartered in Reykjavik, Iceland. | Commercial Services |
Elixir Pharmaceuticals, Inc.
Elixir Pharmaceuticals, Inc. Investment Trusts/Mutual FundsMiscellaneous Elixir Pharmaceuticals, Inc. operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases such as diabetes and obesity. The company was founded by Leonard Guarente, Cynthia J. Kenyon, Cindy Bayley, Louis Kunkel, Annibale Puca, and Thomas Perls in 1999 and is headquartered in Cambridge, MA. | Miscellaneous |
